Exact Sciences is paying $75 million up front for U.S. rights to a colorectal cancer blood test developed by rival Freenome. If approved, Freenome’s liquid biopsy will compete with a blood test from Guardant Health.
The post Exact Sciences Teams Up With Freenome to Take on Guardant Health in Colorectal Cancer Screening appeared first on MedCity News.
